Breast Cancer

Latest News

DNA | Image credit: NHS
Breast Cancer and the Use of Predictive Genomics

June 18th 2025

Data suggest trastuzumab deruxtecan and pertuzumab may represent a new first-line standard of care for metastatic, HER2-positive breast cancer. | Image credit: Axel Kock - stock.adobe.com
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer

June 2nd 2025

AJMC
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

April 4th 2025

Screen-detected breast cancer. | Image Credit: keetazalay - stock.adobe.com
Interval Breast Cancer Risk High Despite Screening, Highlights Need for Risk-Based Approach

March 27th 2025

Diverse women and breast cancer support | Image Credit: ©Atstock Productions-stock.adobe.com
Same-Day Breast Imaging Gaps Reveal Health Care Disparities

February 18th 2025

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

More News

FDA on Paper Texture - Araki Illustrations - stock.adobe.com
October 6th 2023

FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer

Kristi Rosa
The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a poly (ADP-ribose) polymerase inhibitor.
Kristine Slam, MD, Central Ohio Surgical Associates
October 3rd 2023

Dr Kristine Slam Discusses Preoperative Practices to Increase Treatment Value for Patients With Breast Cancer

Maggie L. Shaw
In this interview from our recent Institute for Value-Based Medicine® event, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the positive impact that Choosing Wisely and enhanced recovery after surgery, or EROS, protocols have had on patients receiving treatment for breast cancer.
Computer Screen in Hospital Radiology Room: Beautiful Multiethnic Adult Woman Standing Topless Undergoing Mammography Screening Procedure. Screen Showing the Mammogram Scans of Dense Breast Tissues | Image Credit: Gorodenkoff - stock.adobe.com
September 29th 2023

Dato-Dxd Shows Survival Improvements in HR+/HER2– Breast Cancer

Jordyn Sava
The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor–positive (HR+), HER2-negative (HER2–) breast cancer were treated with datopotamab deruxtecan.
Senior woman having mammography scan at hospital with medical technician. Mammography procedure, breast cancer prevention | Image Credit: Peakstock
September 26th 2023

Older Women Have High Rate of Breast Cancer Overdiagnosis

Maggie L. Shaw
Data from fee-for-service Medicare claims that were linked to the Surveillance, Epidemiology, and End Results program were used for this retrospective cohort analysis among women 70 years and older.
pink mask from COVID19 and breast cancer hold by woman hands | Image Credit Sin Filtro
September 22nd 2023

Breast Cancer Risk Linked to Air Pollution Exposure

Maggie L. Shaw
Data from 6 states—California, Florida, Louisiana, New Jersey, North Carolina, and Pennsylvania—and 2 metropolitan areas—Atlanta, Georgia, and Detroit, Michigan—collected through the National Institutes of Health–AARP Diet and Health Study were used for the investigation.
Kristine Slam, MD, FACP, Central Ohio Surgical Associates
September 19th 2023

Dr Kristine Slam: Value-Based Care in Breast Cancer Requires Collaboration

Maggie L. Shaw
In this interview from our Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio, on September 14, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the benefits of value-based care in the breast cancer space.
Breast cancer | Image credit: Axel Kock – stock.adobe.com
September 16th 2023

Diet and Exercise Intervention Associated With Better pCR in TNBC or HR+, HER2– BC

Hayley Virgil
Despite seeming to elicit more pathological complete responses (pCRs) in patients with hormone receptor–positive (HR+), HER2-negative triple-negative breast cancer (BC) receiving neoadjuvant chemotherapy, diet and exercise did not affect relative dose intensity.
diverse group of women wearing pink for breast cancer | Image credit: Rawpixel.com - stock.adobe.com
September 15th 2023

Regional Disparities Remain in Breast Reconstruction for Patients With Breast Cancer

Laura Joszt, MA
While regional variations were identified in rates of breast reconstruction, complications, and cost for patients with breast cancer, these differences did not seem to be associated with any implicit bias.
Breast cancer with lymphatics, medically 3D illustration | Image credit: Axel Kock - stock.adobe.com
September 8th 2023

Condensed Proton Therapy Schedule Shows Promise for Patients With Breast Cancer

Hayden E. Klein
New research suggests conventional fractionated and hypofractionated proton postmastectomy radiotherapy (PMRT) yield similar tolerability and complication rates for patients following mastectomy.
Using Genomic Assays to Learn Which Patients With Breast Cancer Could Get Less Treatment
September 5th 2023

Using Genomic Assays to Learn Which Patients With Breast Cancer Could Get Less Treatment

Mary Caffrey
Coverage from the July 25, 2023, session of the Institute for Value-Based Medicine®, presented by The American Journal of Managed Care® in partnership with Emory's Winship Cancer Institute.
Helping Patients Overcome Health Disparities as a Patient Advocate
August 29th 2023

Helping Patients Overcome Health Disparities as a Patient Advocate

An expert reviews the role of the patient advocate in ensuring that health disparities in metastatic breast cancer are overcome.
Patient Advocate's Role in Shared Decision Making
August 29th 2023

Patient Advocate's Role in Shared Decision Making

An expert describes the patient advocate’s role in shared decision-making with a patient for novel therapeutic options.
Guiding Patients Through Complex Treatment Decisions
August 22nd 2023

Guiding Patients Through Complex Treatment Decisions

An expert reviews best practices for assisting and guiding patients in their journey when navigating complex treatment decisions and options.
Helping Patients With Metastatic Breast Cancer Enroll in Clinical Trials
August 22nd 2023

Helping Patients With Metastatic Breast Cancer Enroll in Clinical Trials

Sonya Negley, IOM, CSMA, describes the patient advocate’s role in helping patients with metastatic breast cancer discover and enroll in clinical trials.
Empowering Patients With Metastatic Breast Cancer
August 15th 2023

Empowering Patients With Metastatic Breast Cancer

Sonya Negley, IOM, CSMA, discusses ways to help patients with metastatic breast cancer feel empowered during their journey.
How Patient Advocates Can Help the Newly Diagnosed
August 15th 2023

How Patient Advocates Can Help the Newly Diagnosed

Sonya Negley, IOM, CSMA, reviews how patient advocates can help patients newly diagnosed with metastatic breast cancer.
In Reversal, USPSTF Draft Recommendation Calls for Breast Cancer Screening at Age 40
May 9th 2023

In Reversal, USPSTF Draft Recommendation Calls for Breast Cancer Screening at Age 40

Mary Caffrey
The task force was motivated by a gap between in breast cancer deaths between Black and White women.
Debra Patt, MD, PhD, MBA, executive vice president, Texas Oncology
April 19th 2023

Dr Debra Patt Addresses Concerns Around Hormonal Birth Control and Breast Cancer Risk

Pearl Steinzor
Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, explains the small potential risk of breast cancer associated with hormonal birth control.
Recent FDA Actions: Spring 2023
April 19th 2023

Recent FDA Actions: Spring 2023

AJMC Staff
In breast cancer, approval for elacestrant and a new indication for sacituzumab govitecan; approval for pirtobrutinib for mantle cell lymphoma.
Debra Patt, MD, PhD, MBA, executive vice president, Texas Oncology
April 11th 2023

Dr Debra Patt Recaps Her Senate Testimony on Prior Authorization Case for a Patient With Breast Cancer

Pearl Steinzor
Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, discusses her recent testimony to the US Senate on a case in which prior authorization caused a 6-week wait for a consult.
kisqali
March 27th 2023

Novartis Reports Positive Topline Results for NATALEE, Phase 3 Trial of Ribociclib in Early Breast Cancer

Mary Caffrey
Results for this study, involving use of this CDK4/6 inhibitor with endocrine therapy, will be presented at an upcoming scientific meeting and submitted to regulators.
Red FDA Approved stamp
March 7th 2023

FDA Expands Abemaciclib Indication in HR+/HER2–, Node+, High-Risk Breast Cancer

Kristi Rosa
The FDA approved an expanded indication for abemaciclib (Verzenio) in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)–positive, HER2-negative, node-positive, early breast cancer that is at a high risk of recurrence.
Debra Patt, MD, PhD, MBA: DESTINY-Breast04 Realizes a Promise of Modern Cancer Therapy
February 21st 2023

Debra Patt, MD, PhD, MBA: DESTINY-Breast04 Realizes a Promise of Modern Cancer Therapy

Hayden E. Klein
Neil Iyengar, MD
February 21st 2023

Neil Iyengar, MD, Emphasizes Importance of Population Health Lens in Oncology

Hayden E. Klein
image of breast cancer
January 27th 2023

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer

Chris Ryan
The FDA has approved elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.
Trastuzumab Deruxtecan Wins Rapid Approval for HER2-Low Breast Cancer
August 6th 2022

Trastuzumab Deruxtecan Wins Rapid Approval for HER2-Low Breast Cancer

Mary Caffrey
The approval came exactly 2 months after results from the landmark DESTINY-Breast04 trial showed that the antibody drug conjugate reduced the risk of disease progression or death by 50% compared with chemotherapy for HER2-low patients with both hormone receptor (HR)–positive and HR-negative disease.
Debra Patt, MD, PhD, MBA
July 24th 2022

Dr Debra Patt on Capturing the HER2-Low Population

Laura Joszt, MA
Understanding that patients who are HER2-low are different from patients who are HER2-positive and -negative means having the right way to evaluate and identify these patients, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.
Hope S. Rugo, MD, FASCO, University of California San Francisco Helen Diller Family Comprehensive Cancer Center
June 16th 2022

Dr Hope S. Rugo Discusses Clinical Trial Minority Recruitment, PALOMA-2 Findings

Mary Caffrey Maggie L. Shaw
Hope S. Rugo, MD, FASCO, is professor of medicine and the director of the Breast Oncology and Clinical Trials Education program at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. She discusses her experience with palbociclib and letrozole in advanced breast cancer.
Debra Patt, MD, PhD, MBA, Texas Oncology
May 11th 2022

Dr Debra Patt Addresses the Importance of Cancer Screening Awareness, Strong Health Care Infrastructure

Mary Caffrey Maggie L. Shaw
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how community oncology practices have heightened their outreach efforts to entice patients back in for cancer screenings and the importance of thinking outside the box to overcome staffing shortages in the oncology space.
Ribociclib Data Show Reduced Mortality Risk in HR+/HER2- Advanced Breast Cancer
May 9th 2022

Ribociclib Data Show Reduced Mortality Risk in HR+/HER2- Advanced Breast Cancer

Mary Caffrey
Officials from Novartis emphasized that the ribociclib-fulvestrant combination is the only one in the CDK4/6 inhibitor class to demonstrate an overall survival benefit when used in a first-line setting among postmenopausal women.
<123456789
...
13>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo